CRO giant inVentiv Health is opening an early-stage clinic in Miami, expanding its global Phase I services to the U.S. with an emphasis on complex studies.
The new outpost, set to come online in the second half of the year, will feature space for 65 patients at the University of Miami Life Science and Technology Park. The facility will complement inVentiv's Phase I hub in Quebec and focus on multi-step trials, including tests on drug interaction, biosimilars and generics.
The over-arching goal, the company said, is to broaden its Phase I footprint to more quickly get clients into the proof-of-concept stage with the data they need.
"The location of the clinic--in the U.S., specifically in Miami--will help provide broad patient access thanks to a large population and diverse demographic," inVentiv Early Stage President Riaz Bandali said in a statement. "This should enable us to better meet the needs of our clients as they navigate the complex regulatory environment of drug development and approval."
InVentiv, a privately held CRO conglomerate, has been steadily growing its global reach and expertise over the past few years. The company touts itself as playing a role in either the development or commercialization of 60% of all drugs approved by the FDA over the last 5 years. The sprawling company has offerings spanning all phases of clinical development, along with legal, regulatory and policy work, among other services.
- read the statement